ONCAlert | Upfront Therapy for mRCC

Lung Cancer VIEW MORE >>

The FDA granted an Investigational Device Exemption approval to the Personal Genome Diagnostics Inc. elioTM tissue complete assay for use in a Merck trial evaluating pembrolizumab combinations in non–small cell lung cancer, according to a press release from PGDx, developer of the assay.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.